Observation on clinical efficacy of doxofylline and aminophylline in the treatment of bronchial asthma
Objective To explore the clinical value of doxofylline and aminophylline in the treatment of bronchial asthma.Methods 100 patients with bronchial asthma were selected as the study subjects.They were divided into a study group and a control group according to dice-throwing method,with 50 patients in each group.The control group received aminophylline treatment,while the study group received doxofylline treatment.Comparison was made on clinical efficacy,symptom improvement time,incidence of complications,peak expiratory flow rate as a percentage of the predicted value and asthma control test(ACT)score before and after treatment between the two groups.Results After treatment,the total effective rate of the study group was 98.00%,which was higher than 84.00%in the control group,and there was a significant difference between the two groups(P<0.05).The remission time of rale,wheezing and cough in the study group were(5.01±1.21),(3.01±1.56)and(5.01±1.32)d,which were shorter than(6.03±1.26),(4.05±1.51)and(6.36±1.51)d in the control group,and there was a significant difference between the two groups(P<0.05).Before treatment,there was no significant difference in peak expiratory flow rate as a percentage of the predicted value and ACT score between the two groups(P>0.05).After treatment,the peak expiratory flow rate as a percentage of the predicted value and ACT score in both groups were higher than those before treatment;the study group had peak expiratory flow rate as a percentage of the predicted value of(92.16±5.16)%and ACT score of(22.65±2.51)points,which were higher than(86.53±6.33)%and(18.63±3.01)points in the control group;there was a significant difference between the two groups(P<0.05).The incidence of adverse reactions in the study group was 8.00%(4/50),which had no significant difference compared with 10.00%(5/50)in the control group(P>0.05).Conclusion Compared with aminophylline,doxofylline has better clinical efficacy in improving patients with bronchial asthma,and has certain promotion and application value.
万方数据
维普
